Background: Urinary bladder tumor is the seventh most common worldwide tumor . According to National Cancer Institute in Egypt , urinary bladder tumor constitutes 30% of all cancer cases with an incidence rate of 13.5/100,000 individuals. CD10 protein has been an immediate part in pathways of transduction that control cellular development , apoptosis , metastatic possibilities of cancer cells and influence on invasion .CD10 has prognostic incentive in bladder cancer. HER2/neu protein seems to assume a part in neoplastic cell and included in pathogenesis of urinary bladder carcinoma. Association of HER2 receptor in proliferation of invasive urothelial carcinomas has incited trials to HER2/neu targeted therapies in advanced diseases.
Aim of work: To evaluate the immunohistochemical expression of CD10 and HER2/ neu with the pathological parameters of urothelial carcinoma of urinary bladder well as grade and stage versus chronic cystitis
Methods: CD10 and HER2/neu expressions were retrospectively analysed by immunohistochemistry in 30 cases of chronic cystitis and 30 paraffin-embedded specimens of patients with primary urothelial carcinoma (UC).The expressions were related to clinicopathological parameters ,well as grade and pathological stage
Results: The immunohistochemial expression of CD10 and HER2/neu were negative(score 0) in chronic cystitis cases than urothelial carcinoma and was significantly (p < 0.05). Nineteen cases (63%) of primary urothelial carcinomas were positive for CD10 expression and 17 cases (56.7%) were positive for HER2/neu compared to chronic cystitis . The high grade of urothelial carcinoma and the high pathological stage were significantly connected with the high CD10 and HER2/neu expression (p < 0.05).
Conclusion : High CD10 and HER2/neu expression was related to high grade and pathological stage of urothelial carcinoma.